HOPE-1
Details
- Therapeutic approach
- Mucociliary Clearance
- Trial status
- Closed with results Participating Centres
- Trials Tracker ID
- TT001791
- Last updated
- 02/10/2017
Full title
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis (HOPE-1 Study: Hydration for Optimal Pulmonary Effectiveness)
Study detailsEvaluation of potential mucus clearing treatment for all patients with CF regardless of mutation
- Phase
- Phase 2
- Recruitment target
- 80
- CF sponsor
- Spyryx Biosciences, Inc.
- CF sponsor type
- Commercial
Who can take part?
- Age range
- 18 years and older
- Including people
Age 18 years or older
Stable CF Lung Disease- Excluding people
Significant unstable co-morbidities within 28 days of screening.
Has received an investigational drug within 28 days of screening
Get in touch